- In adults with severe COVID-19, remdesivir compared with placebo probably improves recovery by a large amount (absolute risk difference [ARD] range, 7% to 10%) and may result in a small reduction in mortality (ARD range, -4% to 1%) and a shorter time to recovery or clinical improvement. https://www.acpjournals.org/doi/10.7326/m20-5752 9 comments science
Linked pages
- Jun 29 Open Letter from Gilead CEO Daniel O’Day | Stories@Gilead https://stories.gilead.com/articles/an-open-letter-from-daniel-oday-june-29 109 comments
- Remdesivir for the Treatment of Covid-19 — Final Report | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 55 comments
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2015301 6 comments